Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Nyxoah sets price for U.S. public offering at $9.25 per share

EditorNatashya Angelica
Published 05/23/2024, 01:02 PM
© Reuters.
NYXH
-

MONT-SAINT-GUIBERT, Belgium - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company specializing in the treatment of Obstructive Sleep Apnea (OSA), has priced its underwritten public offering in the United States.

The offering includes 5,374,755 ordinary shares at $9.25 each, with an anticipated gross proceeds of approximately $50 million. The offering, which is expected to close on May 28, 2024, is subject to customary closing conditions.

The company also granted underwriters a 30-day option to purchase up to an additional 806,213 shares at the same price. Cantor Fitzgerald & Co. is the sole book-running manager for the offering, with Degroof Petercam serving as a co-manager.

Nyxoah plans to use the net proceeds for various purposes including pre-commercialization and commercialization activities in the U.S., gathering clinical data, financing research and development for the next generation of its Genio system, and other general corporate activities, which may include investments and acquisitions.

The Genio system by Nyxoah is a leadless and battery-free hypoglossal neurostimulation therapy for OSA, a common sleep disorder associated with increased mortality risk and cardiovascular conditions. The company aims to offer OSA patients solutions that enable them to enjoy restful nights and a better quality of life.

This offering is made pursuant to an effective shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission and became effective on January 6, 2023. The final prospectus supplement and accompanying prospectus, when available, can be obtained from Cantor Fitzgerald & Co.

It is important to note that this press release does not constitute an offer to sell or a solicitation of an offer to buy these securities. The offering is available only to qualified or institutional investors and is not open to the public in jurisdictions where such an offering would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The company has taken necessary steps to comply with regulatory requirements, including the related parties procedure of Article 7:97 of the Belgian Companies and Associations Code in connection with the potential participation of Robert Taub, the chairman of the board, in the offering.

This news is based on a press release statement from Nyxoah.

InvestingPro Insights

As Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) proceeds with its public offering in the United States, the company's financial and market metrics provide a clearer picture for potential investors. With a market capitalization of $259.86 million, Nyxoah is positioning itself to leverage the proceeds from this offering to further its commercial and developmental ambitions.

An InvestingPro Tip highlights that analysts are anticipating sales growth in the current year, which aligns with the company's aggressive commercialization plans in the U.S. This optimism is further supported by the substantial revenue growth Nyxoah has experienced over the last twelve months, with a notable increase of 78.99%. This figure suggests a strong upward trajectory in the company's sales performance, potentially enhancing investor confidence.

On the flip side, another InvestingPro Tip indicates that analysts do not expect the company to be profitable this year, which is corroborated by a negative P/E ratio of -6.44. This metric may raise caution among investors, as it reflects the company's current lack of profitability. Moreover, the cash burn concern is substantiated by the company's operating income margin at -895.46%, highlighting the significant expenses incurred in relation to its revenue.

Still, the company's liquid assets surpassing short-term obligations suggest a degree of financial stability that could reassure investors of its ability to meet immediate financial commitments. For those interested in a deeper analysis, there are additional InvestingPro Tips available that could provide further insights into Nyxoah's financial health and market position.

To explore these insights and more, potential investors can visit https://www.investing.com/pro/NYXH. And for those ready to take their investment research to the next level, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking access to a wealth of expert financial analysis and tips.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.